Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness
Authors
Woods, BSSideris, E
Sydes, MR
Gannon, MR
Parmar, MKB
Alzouebi, M
Attard, G
Birtle, AJ
Brock, S
Cathomas, R
Chakraborti, PR
Cook, A
Cross, WR
Dearnaley, D
Gale, J
Gibbs, S
Graham, JD
Hughes, R
Jones, RJ
Laing, R
Mason, MD
Matheson, D
McLaren, DB
Millman, R
O'Sullivan, JM
Parikh, O
Parker, CC
Peedell, C
Protheroe, A
Ritchie, AWS
Robinson, A
Russell, JM
Simms, MS
Srihari, NN
Srinivasan, R
Staffurth, JN
Sundar, S
Thalmann, GN
Tolan, S
Tran, Anna T
Tsang, D
Wagstaff, J
James, ND
Sculpher, MJ
Affiliation
Centre for Health Economics, University of York, York, UK.Issue Date
2019
Metadata
Show full item recordCitation
Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, et al. Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. Eur Urol Oncol. 2018 Dec;1(6):449-58.Journal
European Urology OncologyDOI
10.1016/j.euo.2018.06.004PubMed ID
31158087Additional Links
https://dx.doi.org/10.1016/j.euo.2018.06.004Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.euo.2018.06.004
Scopus Count
Collections
Related articles
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
- Authors: James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK, STAMPEDE investigators
- Issue date: 2016 Mar 19
- A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
- Authors: Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, Kim SP, Konety BR
- Issue date: 2019 Nov
- Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
- Authors: Zhang P, Wen F, Fu P, Yang Y, Li Q
- Issue date: 2017 Jul 31
- Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
- Authors: Clarke CS, Hunter RM, Gabrio A, Brawley CD, Ingleby FC, Dearnaley DP, Matheson D, Attard G, Rush HL, Jones RJ, Cross W, Parker C, Russell JM, Millman R, Gillessen S, Malik Z, Lester JF, Wylie J, Clarke NW, Parmar MKB, Sydes MR, James ND
- Issue date: 2022
- Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
- Authors: Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AWS, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O'Sullivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB, James ND, STAMPEDE Investigators
- Issue date: 2018 May 1